Brad Jordan PhD Eli Lilly and Company

Brad Jordan is the Associate Vice President for Regulatory Policy & Strategy at Eli Lilly and is the policy lead for the cardiometabolic health therapeutic areas. Brad's previous roles include 3 years leading regulatory policy for Flatiron Health and 17 years in the Discovery Research and Regulatory Affairs organizations at Amgen, where he led global regulatory policy strategy for biologics and biosimilars and established regulatory policy support for Amgen’s oncology therapeutic area. During that time, he represented Amgen in numerous trade associations, including PhRMA, BIO, and IFPMA, and was responsible for initiating and leading numerous engagements with global regulatory bodies (FDA, Health Canada, EMA, MHRA, and WHO), resulting in substantial impact in several key policy areas. Prior to Amgen, Brad did his postdoctoral fellowship at St. Jude Children’s research hospital, where he studied the mechanism of bacterial infections and was a co-developer of a peptide-based meningitis vaccine. Brad received his PhD in Biochemistry from the University of Arkansas in 2004.